INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Form 8-K — Oct 21, 2026
Integra LifeSciences (IART) reported Q3 2026 revenues of $411.2 million, up 2.3% reported and 2.5% organic, with GAAP EPS of $0.19 versus $(0.07) a year ago and adjusted EPS of $0.59 versus $0.54.
Key figures
- Eps
- 0.19
- Revenue
- 411200000
- Guidance
- Q4 2026 revenues $413M-$433M; FY2026 revenues $1.634B-$1.654B; FY adjusted EPS $2.30-$2.40; operating cash flow ~$190M-$200M
- Net Income
- 14852000
- Revenue Yoy
- 2.3% reported / 2.5% organic
- Cash Position
- 252261000
- Net debt
- 1516770000
- Adjusted eps
- 0.59
- Leverage ratio
- 3.8x
- Adjusted ebitda
- 79800000
- Total liquidity
- 559000000
- Refinancing size
- 2100000000
- Free cash flow q3
- 85731000
- Gaap gross margin
- 51.0%
- Adjusted gross margin
- 61.1%
- Operating cash flow q3
- 96000000
- Cincinnati revenue impact
- $7 million
- Senior secured notes rate
- 9.5% due 2033
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.